Clinical Trials | April 08, 2026
Amgen’s TEPEZZA injection clears Phase 3 trial with high efficacy
The trial also demonstrated significant improvements across multiple secondary endpoints
The trial also demonstrated significant improvements across multiple secondary endpoints
Safety was equally impressive. ENV-294 was well tolerated
Participants also experienced a VR-enabled learning environment designed to support clinical skill development in controlled, repeatable, and risk-free settings
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The center brings together hands on technology demonstrations, application expertise, and commercial operations
Subscribe To Our Newsletter & Stay Updated
